Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NEO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNeoGenomics reports Q1 2026 financial results
Filed April 28, 2026 · Period ending April 28, 2026 · ~1 min read
Key Changes
-
high
NeoGenomics issued a press release on April 28, 2026 disclosing first quarter 2026 financial results. Specific revenue, earnings, and operational metrics are contained in the attached press release (Exhibit 99.1).
Item 2.02 verify on EDGAR → -
medium
The 8-K filing itself contains no financial details; investors must review the attached press release exhibit to assess quarterly performance and management commentary.
8-K: Exhibit 99.1 view on EDGAR →
Summary
NeoGenomics announced its first quarter 2026 financial results through a press release on April 28, 2026. This is a routine quarterly earnings disclosure required for publicly traded companies. The 8-K filing serves as the formal SEC notification mechanism, but the actual financial performance data—including revenue, net income, earnings per share, and operational metrics—are contained in the attached press release exhibit rather than in the body of the filing itself.
Retail investors should review the full press release (Exhibit 99.1) to understand how NeoGenomics performed against analyst expectations and prior guidance. Key items to watch include year-over-year revenue growth trends, profitability metrics, and any updated forward guidance for the remainder of 2026. Management commentary on test volume trends, reimbursement rates, and competitive positioning will provide insight into the company's near-term trajectory in the oncology diagnostics market.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 28, 2026, NeoGenomics, Inc. issued a press release reporting its results for its first fiscal quarter of 2026.
NeoGenomics disclosed its first quarter 2026 financial results through a press release. The actual financial metrics and performance details are contained in the attached press release exhibit, which is not included in this 8-K body text.
Event · Item 9.01 — Financial Statements and Exhibits
NeoGenomics filed an 8-K attaching a press release dated April 28, 2026; no material event details disclosed in the filing body.
Added in current filing · view on EDGAR →
99.1
Press Release of NeoGenomics, Inc. dated April 28, 2026.
The 8-K references an attached press release dated April 28, 2026. The filing body does not disclose the content of the press release, so the nature and materiality of the event cannot be determined from this document alone. Investors should review Exhibit 99.1 for details.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify